
Vendel A. Kristensen
- Consultant, Postdoc; MD
Education:
- MD University of Bergen (2001)
- PhD University of Oslo (2016)
- Norwegian clinical specialist accreditations: Internal medicine (2012) and gastroenterology (2017)
Current position:
Consultant, Department of gastroenterology, Oslo University Hospital
Publications 2025
Prevalence of Irritable Bowel Syndrome Based on Rome IV Criteria in Patients in Biochemical and Endoscopic Remission From Newly Diagnosed Inflammatory Bowel Disease: One- and Three-Year Results (the IBSEN III Cohort)
Inflamm Bowel Dis (in press)
DOI 10.1093/ibd/izaf047, PubMed 40063582
Habitual Intake of Macronutrients and Fermentable Oligo-, Di-, Monosaccharides and Polyols is not associated with Irritable Bowel Syndrome-like Symptoms in Inflammatory Bowel Disease
Clin Nutr ESPEN (in press)
DOI 10.1016/j.clnesp.2025.03.005, PubMed 40064237
Publications 2024
Assessing hard and loose "endpoints": comparison of patient and expert Bristol Stool Scale scoring of 2280 fecal samples
F1000Res, 13, 833
DOI 10.12688/f1000research.152496.2, PubMed 39872194
Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study)
J Crohns Colitis (in press)
DOI 10.1093/ecco-jcc/jjae170, PubMed 39527064
Low Surgery Rates in Early Crohn's Disease: Results from a Prospective Population-Based Inception Cohort-The Inflammatory Bowel Disease in South-Eastern Norway III Study
Inflamm Bowel Dis (in press)
DOI 10.1093/ibd/izae297, PubMed 39699202
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply
Aliment Pharmacol Ther, 60 (6), 831-832
DOI 10.1111/apt.18187, PubMed 39072820
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
Aliment Pharmacol Ther, 60 (3), 357-368
DOI 10.1111/apt.18097, PubMed 38837289
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 59 (6), 652-660
DOI 10.1080/00365521.2024.2313056, PubMed 38356408
Publications 2023
Intraoperative distensibility measurement in POEM for achalasia: impact on patient outcome and associations with other outcome variables at 1-year follow-up
Surg Endosc, 37 (12), 9283-9290
DOI 10.1007/s00464-023-10494-z, PubMed 37880446
Fatigue in Patients with Newly Diagnosed Inflammatory Bowel Disease: Results from a Prospective Inception Cohort, the IBSEN III Study
J Crohns Colitis, 17 (11), 1781-1790
DOI 10.1093/ecco-jcc/jjad094, PubMed 37279652
Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study
BMC Gastroenterol, 23 (1), 255
DOI 10.1186/s12876-023-02889-y, PubMed 37501083
Health-related quality of life in patients with newly diagnosed inflammatory bowel disease: an observational prospective cohort study (IBSEN III)
Qual Life Res, 32 (10), 2951-2964
DOI 10.1007/s11136-023-03435-9, PubMed 37219727
Publications 2022
Quality of life in patients with achalasia: Associations with Eckardt score and objective treatment outcomes after peroral endoscopic myotomy
Endosc Int Open, 10 (12), E1570-E1576
DOI 10.1055/a-1968-7682, PubMed 36531682
Publications 2021
One year comprehensive prospective follow-up of achalasia patients after peroral endoscopic myotomy
Ann Med, 53 (1), 2225-2233
DOI 10.1080/07853890.2021.2005253, PubMed 34806501
Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway
Scand J Gastroenterol, 56 (8), 899-905
DOI 10.1080/00365521.2021.1922746, PubMed 34154494
Publications 2020
Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study
Scand J Gastroenterol, 55 (4), 436-441
DOI 10.1080/00365521.2020.1745879, PubMed 32252542
Publications 2019
Outcome of peroral endoscopic myotomy (POEM) in treatment-naive patients. A systematic review
Scand J Gastroenterol, 54 (1), 1-7
DOI 10.1080/00365521.2018.1549271, PubMed 30650313
Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease
Scand J Gastroenterol, 54 (5), 571-576
DOI 10.1080/00365521.2019.1608467, PubMed 31050907
Publications 2017
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
Gastroenterol Res Pract, 2017, 2098293
DOI 10.1155/2017/2098293, PubMed 29225617
Publications 2016
Patient-performed extraction of faecal calprotectin
Clin Chem Lab Med, 54 (8), 1357-63
DOI 10.1515/cclm-2015-1037, PubMed 26812797
Publications 2015
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin
J Crohns Colitis, 9 (2), 164-9
DOI 10.1093/ecco-jcc/jju015, PubMed 25518057
Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods
Scand J Clin Lab Invest, 75 (5), 355-61
DOI 10.3109/00365513.2015.1030765, PubMed 25856663
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure
Scand J Gastroenterol, 51 (5), 548-55
DOI 10.3109/00365521.2015.1117650, PubMed 26634305
Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease
Scand J Gastroenterol, 50 (9), 1183-4
DOI 10.3109/00365521.2015.1025830, PubMed 25772406